UDX

UDX

Private
SpainHealthcare & Life Scienceswww.universaldx.com

Last Round

Debt

Feb 27, 2025

Total Funding Raised

$125.91M

Momentum Score

25 /100

Company Overview

Universal Diagnostics DX is a bioinformatics and multi-omics company that develops innovative, minimally invasive blood tests utilizing proprietary tools and machine learning algorithms to detect cancer at its earliest stages, aiming to make the disease preventable and curable.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical Devices

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

liquid biopsyearly cancer detectioncolorectal cancer screeningcancer diagnosticscell-free DNADNA methylationcfDNAmulti-cancer detectionMCEDSignal-Cin-vitro diagnosticIVDadenoma detectionCE mark

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

UDX Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

UDX Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
DebtFeb 27, 2025
Series BAug 7, 2024
DebtFeb 27, 2024
AngelAug 16, 2018
SeedJun 1, 2013

Key People

Founding team and executive leadership

Diego Broseta

Chief Financial Officer

Executive Team

Christian Hense

Chief Operating Officer (COO)

Executive Team

UDX Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2026

    Hiring for Clinical Research Associate indicates diagnostic test trials are in progress.

  • Jan 1, 2026

    Undergoing FDA Premarket Approval for Class III diagnostic device Signal-C.

UDX Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

UDX Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about UDX's valuation, stock price, and market status.

Firmographic Details

HeadquartersSpain
Employee Range118
Year Founded2012
Last FundingFeb 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.